Collegium Pharmaceutical, Inc.

NasdaqGS:COLL Voorraadrapport

Marktkapitalisatie: US$1.1b

Collegium Pharmaceutical Balans Gezondheid

Financiële gezondheid criteriumcontroles 4/6

Collegium Pharmaceutical heeft een totaal eigen vermogen van $216.6M en een totale schuld van $552.8M, wat de schuld-eigenvermogensverhouding op 255.3% brengt. De totale activa en totale passiva bedragen respectievelijk $1.1B en $836.8M. De EBIT Collegium Pharmaceutical is $203.8M waardoor de rentedekking 3.7 is. Het heeft contanten en kortetermijnbeleggingen van $271.6M.

Belangrijke informatie

255.3%

Verhouding schuld/eigen vermogen

US$552.83m

Schuld

Rente dekkingsratio3.7x
ContantUS$271.63m
AandelenUS$216.58m
Totaal verplichtingenUS$836.81m
Totaal activaUS$1.05b

Recente financiële gezondheidsupdates

Recent updates

Is Collegium Pharmaceutical (NASDAQ:COLL) A Risky Investment?

Oct 28
Is Collegium Pharmaceutical (NASDAQ:COLL) A Risky Investment?

Collegium Pharmaceutical: Diversifying And Growing

Aug 09

Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) Price Is Right But Growth Is Lacking

Jul 24
Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) Price Is Right But Growth Is Lacking

Collegium Pharmaceutical (NASDAQ:COLL) Seems To Use Debt Quite Sensibly

Jun 05
Collegium Pharmaceutical (NASDAQ:COLL) Seems To Use Debt Quite Sensibly

Collegium Pharmaceutical: Some Positives From Its Quarterly 'Miss'

May 13

It Looks Like Shareholders Would Probably Approve Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) CEO Compensation Package

May 10
It Looks Like Shareholders Would Probably Approve Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) CEO Compensation Package

Collegium Pharmaceutical Q4: The Beat Goes On

Feb 26

These 4 Measures Indicate That Collegium Pharmaceutical (NASDAQ:COLL) Is Using Debt Reasonably Well

Feb 24
These 4 Measures Indicate That Collegium Pharmaceutical (NASDAQ:COLL) Is Using Debt Reasonably Well

There's No Escaping Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) Muted Revenues

Jan 05
There's No Escaping Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) Muted Revenues

Here's Why Collegium Pharmaceutical (NASDAQ:COLL) Can Manage Its Debt Responsibly

Nov 12
Here's Why Collegium Pharmaceutical (NASDAQ:COLL) Can Manage Its Debt Responsibly

Is Collegium Pharmaceutical (NASDAQ:COLL) Using Too Much Debt?

Aug 09
Is Collegium Pharmaceutical (NASDAQ:COLL) Using Too Much Debt?

Is Collegium Pharmaceutical (NASDAQ:COLL) A Risky Investment?

Mar 10
Is Collegium Pharmaceutical (NASDAQ:COLL) A Risky Investment?

Is Collegium Pharmaceutical (NASDAQ:COLL) Using Too Much Debt?

Oct 18
Is Collegium Pharmaceutical (NASDAQ:COLL) Using Too Much Debt?

Collegium Pharmaceutical (NASDAQ:COLL) Has A Somewhat Strained Balance Sheet

Jun 24
Collegium Pharmaceutical (NASDAQ:COLL) Has A Somewhat Strained Balance Sheet

Collegium Pharmaceutical: Oversold And Cheap

Jun 12

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( $510.2M ) COLL } overtreffen de korte termijn passiva ( $461.7M ).

Langlopende schulden: De kortetermijnactiva COLL ( $510.2M ) overtreffen de langetermijnschulden ( $375.1M ).


Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: De netto schuld/eigen vermogen ratio ( 129.8% ) COLL wordt als hoog beschouwd.

Schuld verminderen: De schuld/eigen vermogen-ratio van COLL is de afgelopen 5 jaar gestegen van 13.4% naar 255.3%.

Schuldendekking: De schuld van COLL wordt goed gedekt door de operationele kasstroom ( 50.1% ).

Rentedekking: De rentebetalingen op de schuld van COLL worden goed gedekt door EBIT ( 3.7 x dekking).


Balans


Ontdek gezonde bedrijven